Top

Open Access 03-04-2024 | Vulvar Cancer | Original Article

Significance of definitive concurrent chemoradiotherapy for vulvar cancer: a Japanese Gynecologic Oncology Group nationwide survey study

Authors: Noriyuki Okonogi, Keisuke Tsuchida, Ken Ando, Tatsuya Ohno, Hiroyuki Fujiwara, Kosuke Yoshihara, Takuya Aoki, Hirokuni Takano, Munetaka Takekuma, Aikou Okamoto, Shin Nishio

Published in: Japanese Journal of Radiology

Abstract

Objective

This study aimed to show the results of radical radiation therapy (RT) and concurrent chemoradiotherapy (CCRT) for vulvar cancer (VC) based on data from a Japanese nationwide survey.

Materials and methods

We collected data from 108 institutions on cases of VC diagnosed between January 2001 and December 2010. Patients with histologically proven squamous cell carcinoma and adenocarcinoma with curative intent were selected, and 172 patients with VC were included in this study. The collected data were analyzed for overall survival (OS) using the Kaplan–Meier method. Univariate and multivariate analyses were performed to examine the prognostic factors for patients with VC.

Results

The median follow-up period was 16.8 (range; 3.2–154.8) months. Fifty-five patients received CCRT, and 117 patients received RT alone. The 2-year OS rates (95% confidence interval [CI]) for stages I, II, III, and IV were 77.9% (55.8–100.0), 71.9% (53.8–89.9), 55.4% (42.5–68.3), and 41.5% (27.3–55.7) respectively. Univariate analyses showed that the FIGO stage (p = 0.001), tumor diameter (p = 0.005), and lymph node (LN) status (p = 0.001) were associated with OS. The concurrent use of chemotherapy resulted in a significantly longer OS in Stage III (p = 0.013). Multivariate analysis showed that the hazard ratios (95% CI) for tumor diameter, positivity for LN metastasis, and RT alone (no concurrent chemotherapy) were 1.502 (1.116–2.021), 1.801 (1.287–2.521), and 1.936 (1.187–3.159), respectively.

Conclusions

Our analysis revealed that CCRT should be recommended, especially for Stage III VC patients. Further studies are warranted to determine who benefits from CCRT, considering primary tumor size and LN status.

The study was registered at the University Hospital Medical Information Network (protocol number: UMIN000017080) on April 8th, 2015.

Bucchi L, Pizzato M, Rosso S, Ferretti S. New insights into the epidemiology of vulvar cancer: systematic literature review for an update of incidence and risk factors. Cancers (Basel). 2022;14:389. https://doi.org/10.3390/cancers14020389.CrossRefPubMed

Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R, et al. Cancer Incidence in Five Continents. Volume XI, International Agency for Research on Cancer, Lyon, France, 2017. (Electronic version).

The National Comprehensive Cancer Network, V. Cancer, 2023. https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf (accessed 21 October 2023).

Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol. 1986;68:733–40.PubMed

Faul CM, Mirmow D, Huang Q, Gerszten K, Day R, Jones MW. Adjuvant radiation for vulvar carcinoma: improved local control. Int J Radiat Oncol Biol Phys. 1997;38:381–9. https://doi.org/10.1016/s0360-3016(97)82500-x.CrossRefPubMed

Moore DH, Ali S, Koh WJ, Michael H, Barnes MN, McCourt CK, et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol. 2012;124(3):529–33. https://doi.org/10.1016/j.ygyno.2011.11.003.CrossRefPubMed

Natesan D, Susko M, Havrilesky L, Chino J. Definitive chemoradiotherapy for vulvar cancer. Int J Gynecol Cancer. 2016;26(9):1699–705. https://doi.org/10.1097/IGC.0000000000000811.CrossRefPubMed

van Triest B, Rasing M, van der Velden J, de Hullu J, Witteveen PO, Beukema JC, et al. Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: an efficacy study. Gynecol Oncol. 2021;163:117–24. https://doi.org/10.1016/j.ygyno.2021.07.020.CrossRefPubMed

Nishio S, Murotani K, Nakao S, Takenaka M, Suzuki S, Aoki Y, et al. Investigation of clinicopathological features of vulvar cancer in 1068 patients: a Japanese Gynecologic Oncology Group (JGOG) nationwide survey study. Gynecol Oncol. 2020;159:449–55. https://doi.org/10.1016/j.ygyno.2020.08.019.CrossRefPubMed

10.

Han SC, Kim DH, Higgins SA, Carcangiu ML, Kacinski BM. Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva. Int J Radiat Oncol Biol Phys. 2000;47:1235–44. https://doi.org/10.1016/s0360-3016(00)00569-1.CrossRefPubMed

11.

Landoni F, Maneo A, Zanetta G, Colombo A, Nava S, Placa F, et al. Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. Gynecol Oncol. 1996;61:321–7. https://doi.org/10.1006/gyno.1996.0150.CrossRefPubMed

12.

Lupi G, Raspagliesi F, Zucali R, Fontanelli R, Paladini D, Kenda R, et al. Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. Cancer. 1996;77:1472–8. https://doi.org/10.1002/(SICI)1097-0142(19960415)77:8%3c1472::AID-CNCR8%3e3.0.CO;2-E.CrossRefPubMed

13.

Mak RH, Halasz LM, Tanaka CK, Ancukiewicz M, Schultz DJ, Russell AH, et al. Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva. Gynecol Oncol. 2011;120:101–7. https://doi.org/10.1016/j.ygyno.2010.09.004.CrossRefPubMed

14.

Rao YJ, Chin RI, Hui C, Mutch DG, Powell MA, Schwarz JK, et al. Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: a review of the National Cancer Database. Gynecol Oncol. 2017;146:572–9. https://doi.org/10.1016/j.ygyno.2017.06.022.CrossRefPubMed

15.

Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jahshan A, et al. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol. 1991;164:997–1003. https://doi.org/10.1016/0002-9378(91)90573-a.CrossRefPubMed

16.

Burger MP, Hollema H, Emanuels AG, Krans M, Pras E, Bouma J. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol Oncol. 1995;57:327–34. https://doi.org/10.1006/gyno.1995.1151.CrossRefPubMed

17.

Laliscia C, Fabrini MG, Cafaro I, Barcellini A, Baldaccini D, Miniati M, et al. Adjuvant radiotherapy in high-risk squamous cell carcinoma of the vulva: a two-institutional Italian experience. Oncol Res Treat. 2017;40:778–83. https://doi.org/10.1159/000479876.CrossRefPubMed

18.

Stecklein SR, Frumovitz M, Klopp AH, Gunther JR, Eifel PJ. Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy. Gynecol Oncol. 2018;148:474–9. https://doi.org/10.1016/j.ygyno.2018.01.007.CrossRefPubMed

19.

Rishi A, Rollins M, Ahmed KA, Hunt DC, Sarkar P, Fernandez DC, et al. High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: outcome and toxicity. Gynecol Oncol. 2020;156:349–56. https://doi.org/10.1016/j.ygyno.2019.11.027.CrossRefPubMed

Title: Significance of definitive concurrent chemoradiotherapy for vulvar cancer: a Japanese Gynecologic Oncology Group nationwide survey study
Authors: Noriyuki Okonogi
Keisuke Tsuchida
Ken Ando
Tatsuya Ohno
Hiroyuki Fujiwara
Kosuke Yoshihara
Takuya Aoki
Hirokuni Takano
Munetaka Takekuma
Aikou Okamoto
Shin Nishio
Publication date: 03-04-2024
Publisher: Springer Nature Singapore
Keywords: Vulvar Cancer
Vulvar Cancer
Cytostatic Therapy
Metastasis
Published in: Japanese Journal of Radiology
Print ISSN: 1867-1071
Electronic ISSN: 1867-108X
DOI: https://doi.org/10.1007/s11604-024-01557-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Significance of definitive concurrent chemoradiotherapy for vulvar cancer: a Japanese Gynecologic Oncology Group nationwide survey study

Abstract

Objective

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusions

Please log in to get access to this content